Pharmaceuticals
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces an educational webinar exploring the evolution of PSMA[1]-targeted radionuclide therapy and Telix's differentiated, multi-product approach to treating pros...
2026-04-28 07:44
6220
IMG Pharma Enters into Definitive Agreement to Acquire Matsumoto Pharmaceutical
TOKYO, April 27, 2026 /PRNewswire/ -- IMG Pharmaceutical Co., Ltd. ("IMG Pharma"), a majority-owned subsidiary of IMG Japan, the Group's holding company, announced that it has entered into a definitive agreement to acquire Matsumoto Pharmaceutical Co., Ltd., a Japanese pharmaceutical manufacturer...
2026-04-27 16:35
4015
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27, 2026 /PRN...
2026-04-27 08:10
7413
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated with clinically significant ALT elevation. These findi...
2026-04-26 19:00
8149
Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments
* 74 healthcare professionals from 13 countries attended, recognizing the value of PrabotulinumtoxinA's "Safety" * Comprehensive program including anatomy sessions, proprietary injection techniques, and 1:1 hands-on training * Global participants praise the program as "a platform to share pr...
2026-04-24 11:16
5530
Servier completes the acquisition of Day One Biopharmaceuticals
* Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. * Transaction also includes a strong oncology pipeline of clinical stage assetsin rare cancers with high unmet needs. * Transaction represents total equity ...
2026-04-23 20:30
4194
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...
2026-04-23 16:22
6712
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
2026-04-23 15:02
1674
2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative lo...
2026-04-23 10:19
1477
Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration c...
2026-04-23 06:30
4457
Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
BEIJING, April 22, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results...
2026-04-22 11:09
3194
NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes
An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier. ...
2026-04-22 11:00
4327
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs).2 Investment of a...
2026-04-22 10:00
3595
Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
CHENGDU, China, April 22, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, includi...
2026-04-22 08:59
5795
Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 22, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC (bulumtatug fuvedotin, R&D code: 9MW2821) for the treatment ...
2026-04-22 08:00
6287
Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Adminis...
2026-04-21 10:00
5602
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myelom...
2026-04-20 18:45
3825
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per sha...
2026-04-20 10:36
7823
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official journal of the American College of Chest Physicians...
2026-04-20 09:00
5334
ACT Genomics Upgrades Clinically Recognized Genomic Test to 101-Gene Panel with 7-Day Turnaround
TAIPEI, April 20, 2026 /PRNewswire/ -- ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to ...
2026-04-20 09:00
4060
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13475
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12207
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11170
